| Date Filed | Type | Description |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results|
Docs:
|
"Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 3, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.34 per share for the three months ended June 30, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect stable patient volumes and strong cash gene..." |
|
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
SC 13G/A
| ALLIANCEBERNSTEIN L.P. reports a 10% stake in Pediatrix Medical Group Inc |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Pediatrix Medical Group Reports First Quarter Results FORT LAUDERDALE, Fla., May 2, 2023 - Pediatrix Medical Group, Inc. , the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.17 per share for the three months ended March 31, 2023. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.23. For the 2023 first quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $491 million; • Income from continuing operations of $14 million; and • Adjusted EBITDA of $40 million. “Our first quarter operating results were in line with our expectations and reflected modest improvements in revenue cycle managemen..." |
|
| 03/31/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| EARNEST PARTNERS LLC reports a 7.9% stake in Pediatrix Medical Group, Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 0% stake in PEDIATRIX MEDICAL GROUP INC |
| 01/23/2023 |
SC 13G/A
| BlackRock Inc. reports a 16.5% stake in Pediatrix Medical Group, Inc. |
| 01/20/2023 |
SC 13D/A
| Starboard Value LP reports a 4% stake in Pediatrix Medical Group, Inc. |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
SC 13D/A
| Starboard Value LP reports a 7.1% stake in Pediatrix Medical Group, Inc. |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/28/2022 |
8-K
| Quarterly results|
Docs:
|
"Mednax Reports First Quarter Results FORT LAUDERDALE, Fla., April 28, 2022 - Mednax, Inc. , whose affiliated practices operate as Pediatrix® Medical Group, the nation’s leading provider of highly specialized health care for women, children and babies, today reported a loss from continuing operations of $0.25 per share for the three months ended March 31, 2022. Results from continuing operations include a pretax loss on early extinguishment of debt of $57 million. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.33. For the 2022 first quarter, Mednax reported the following results from continuing operations: • Net revenue of $482 million; • Loss from continuing operations of $21 million; and • Adjusted EBITDA of $51 million. “Our..." |
|
| 04/01/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/01/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/25/2022 |
8-K
| Quarterly results |
|